A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
formats

St. Jude Medical Announces Clinical Benefits of Quadripolar CRT Pacing at ACC

Quadrapolar cardiac resynchronization pacing St Jude Medical Unify Quadra www.implantable-device.com

Image Credit: St. Jude Medical

St. Jude Medical announced that clinical findings on quadripolar pacing will be presented at the 61st Annual Scientific Sessions of the American College of Cardiology (ACC, Chicago, March 24-27 2012).

According to St. Jude’s announcement, quadripolar pacing allows physicians the ability to use multisite left-ventricular (LV) pacing.  Studies that examined the role of multisite pacing in improving hemodynamics and reducing dyssynchrony as compared to traditional bi-ventricular pacing will be presented in the following two posters:

Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

FDA AIMD PMA/Supplement Approvals for January

FDA logoFDA released its PMA/Supplement approvals for January.   The edited version below has been edited to include only AIMDs.  It is not the full list, and should be used only for general information purposes.

Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Cool Reed Switch Manufacturing Video

Reed Switch used in implantable medical devices www.implantable-device.com

Magnetic reed switches are used in active implantable medical devices as a simple way of placing the device in a known operational mode when a programmer is not available.  For example, placing a magnet on a pacemaker sets it to VVI mode with a manufacturer-specified set of parameters.  In other devices (e.g. implantable cardioverter/defibrillators), placing a magnet on the IPG inhibits the delivery of high voltage defibrillation.

Although the reed switches that I use don’t come from Meder Electronics, I came across a very cool video that Meder produced regarding their manufacturing process.   Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

ImThera Receives CE Mark for the Aura6000 System to Treat Obstructive Sleep Apnea

 

ImThera Aura 6000 implantable device for the treatment of obstructive sleep apnea

Image Credit: Imthera

ImThera Medical announced this week that it received the CE Mark for the Aura6000 System to Treat Obstructive Sleep Apnea. Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Boston Scientific to Acquire Cameron Health for $150M Up-Front + $150M Upon FDA Approval

Cameron Health S-ICD subcutaneous defibrillator

Image Credit: Boston Scientific

Boston Scientific announced the exercise of its option to acquire Cameron Health.  Cameron Health developed the world’s first and only commercially-available subcutaneous implantable cardioverter defibrillator – the S-ICD® System that I blogged about a few weeks ago.

The agreement calls for an upfront payment of $150 million, payable upon transaction closing, an additional potential $150 million payment upon FDA approval of the S-ICD System, plus up to an additional $1.050 billion of potential payments upon achievement of specified revenue-based milestones over a six-year period following FDA approval.  Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second or third quarter of 2012.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Medtronic Receives CE Mark for CapSure Sense MRI™ SureScan® Pacing Leads

Medtronic SureScan Sense MRI Passive Fixation Leads. www.implantable-device.com

Image Credit: Medtronic

Medtronic today announced the receipt of CE Mark and launch of the CapSure Sense MRI™ SureScan® pacing leads, which are approved for use during MRI procedures.  The newly approved leads are the smallest MR–Conditional leads available in the world with a 5.3 French isodiametric lead body.  The new leads are passive-fixation leads.  Previously approved Medtronic MR–Conditional leads are active fixation leads.

Click here for Medtronic’s product page for the CapSure Sense MRI™ SureScan® Pacing Leads.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
2 Comments  comments 
formats

News from Stanford: Modelling Tissue as a Dielectric Shows Feasibility of Inductive Power Transfer at 1 GHz

Stanford self-propelled implantable device powered at 1 GHz  www.implantable-device.com

Image Credit: Stanford University

Stanford Engineering assistant professor  Ada Poon demonstrated a tiny, wirelessly powered, self-propelled medical device capable of controlled motion through blood.  The device drives electrical current directly through the fluid, which in the presence of an external magnetic field creates a directional force that pushes the device forward. This type of device is capable of moving at just over half-a-centimeter per second.

That was the news picked up by bloggers from Poon’s presentation at the International Solid-State Circuits Conference (ISSCC).  However, what caught my attention is her work on inductive transcutaneous energy transmission.  From Stanford’s press release: Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Medtronic’s Q3 AIMD Earnings: CRM 3% Down, Neuromodulation 4% Up

Today Medtronic announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. According to the report:

“CRDM third quarter revenue of $1.192 billion decreased 2 percent as reported or 3% on a constant currency basis. Third quarter revenue from ICDs was $674 million,  down 9 percent on a constant currency basis, while pacing revenue was $467 million, an increase of 3 percent on a constant currency basis. Weaker ICD sales, primarily due to declining procedure volumes in the U.S. market versus the prior year, were partially offset by continued growth of the AF Solutions and Pacing businesses.”

“Neuromodulation revenue of $419 million increased 4 percent as reported and on a constant currency basis. Growth continues to be driven by strong sales of InterStim® Therapy. The RestoreSensor™ spinal cord stimulator with its proprietary AdaptiveStim™ technology continues to perform well in Europe, and was approved in the U.S. and Japan in the third quarter. The U.S. launch of this product was delayed for most of the quarter due to a supply disruption resulting from the flooding in Thailand, which has subsequently been resolved.”

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

MicroCHIPS Announces Clinical Results for First Successful Human Trial of Programmable Microchip-Based Drug Delivery Device

MicroCHIPS implantable programmable pump for the treatment of osteoporosis

Image Credit: MicroCHIPS, Inc.

Last month I posted some background on MicroCHIPS, the MIT spinoff to develop implantable sensors and drug-delivery devices.  I concluded that post with the February 2011 announcement that MicroCHIPS started its clinical trial to assess the pharmacokinetics of long-term parathyroid hormone (hPTH 1-34) delivery in women with osteoporosis.

MicroCHIPS announced today the results of the first successful human clinical trial with an implantable, wirelessly controlled and programmable microchip-based drug delivery device. The MicroCHIPS study was published in today’s online edition of the journal Science Translational Medicine. Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

iPacemaker Implantable Pacemaker/ICD Database for the iPhone

iPacemaker implantable pacemaker and ICD database for the iPhone

Image Credit: iPacemaker

My friend and colleague Dr. Irit Yaniv alerted me to this iPhone app that was just released.  It is an implantable pacemaker and defibrillator database that, according to its author, displays up to 70 parameters for each model, includes battery and longevity data, and links directly to product manuals. Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

The Australian Pacemaker: Telectronics (1965-1995)

Telectronics model 150B VVI pacemaker photographed by David Prutchi, Ph.D.  www.implantable-device.comIn 1965, Australian medical device pioneer Noel Gray established Telectronics – Australia’s first manufacturing facility for producing pacemakers that were designed in-house.  Telectronics was an innovative developer, achieving some major successes in the early cardiac pacing field, for example, Telectronics’ leads allowed narrowing the pacing pulse to its current nominal of 0.5 milliseconds; encapsulating the pacemaker in titanium instead of epoxy; using a microplasma weld to join the two halves of the pacemaker capsule; creating one of the first rate-responsive ’demand’ pacemakers; and isolating the pacemaker’s battery in a separate compartment to deal with the problem of leaking mercury-zinc batteries. Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
3 Comments  comments 
formats

Micro Systems Technologies Offers Active Implantable Medical Device Development/Manufacturing Services

Micro Systems Technologies offers OEM services to AIMDs

Image Credit: Micro Systems Technologies

Micro Systems Technologies (MST) is the vertically-integrated supplier of microelectronics and implantable-grade components to Biotronik.  It now offers its development and manufacturing services to others.

Through its companies, MST offers high-reliability microelectronic modules for implantable medical devices such as pacemakers, defibrillators, neurostimulators, and cochlear implants.

MST can provide integrated solutions encompassing everything from conceptual design through high-volume surface-mount (SMT) assembly of modules. Services include design development of customer-defined electronic modules, custom ASIC design and development, and high-density-interconnect (HDI) substrate and assembly design.

As a OEM, MST offers state-of-the-art automated SMT line, an ISO 13485–compliant process and component verification and validation methodology, a manufacturing execution system that automates data collection, analysis, and process control, and comprehensive supply-chain management and monitoring with 100% traceability. Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

VeriTeQ Acquisition Corporation Acquires Implantable, FDA-Cleared VeriChip Technology

 

VeriMed's Human-Implantable VeriChip RFID

Image Credit: VeriMed

On January 17, 2012, VeriTeQ Acquisition Corporation of Delray Beach, FL announced that it acquired the VeriChip implantable RFID technology and its related Health Link personal health record from PositiveID Corporation. Read more…

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

DF-4 Connectors for Implantable Cardioverter Defibrillators Enter Use in the US

DF-4 Connector for implantable cardioverter defibrillators

Image Credit: St. Jude Medical

The DF-4 Connector was recently introduced by a joint group of CRM companies, physicians, and regulatory agencies as a way of easing the implant of ICDs by reducing defibrillation connections from three to one and by minimizing the number of set screws.  Prior to the development of the DF-4, traditional high-voltage connector systems required up to three connections. Read more…
 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments 
formats

Boston Scientific’s Active Implantable Sales for 2011: CRM Down 7%, Neuromodulation Up 10%

Boston Scientific Logo

Today Boston Scientific Corporation announced financial results for the fourth quarter and full year ended December 31, 2011.  Summarizing the AIMD data:

  • On a constant-currency basis, Q4 2011 CRM sales were $482M compared to $564M in Q4 2010, or  down 15%
  • On a constant-currency basis, 2011 CRM sales were $2,087M compared to $2,180M in Q4 2010, or  down 7%
  • On a constant-currency basis, Q4 2011 Neuromodulation sales were $91M compared to $86M in Q4 2010, or  up 6%
  • On a constant-currency basis, Q4 2011 CRM sales were $336M compared to $304M in Q4 2010, or  up 10%

Click here for the news release.

 

 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off  comments